Bausch & Lomb Corp BLCO
Bausch + Lomb Corporation (and its subsidiaries) ("Bausch + Lomb," "we," "us," "our" or the "Company") is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Founded in 1853, Bausch + Lomb has a significant global research, development, manufacturing and commercial footprint of approximately 13,000 employees and a presence in approximately 100 countries. As a fully integrated eye health business, Bausch + Lomb has a comprehensive portfolio of approximately 400 products, which includes an established line of contact lenses, intraocular lenses ("IOLs") and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B | — |
| SG&A | $2.23B | $2.08B | $1.74B | $1.48B | $1.39B | $1.25B | — |
| Total operating expenses | $4.99B | $4.63B | $4.02B | $3.56B | $3.44B | $3.15B | — |
| Operating income | $113.0M | $162.0M | $130.0M | $207.0M | $329.0M | $260.0M | — |
| Pre-tax income | -$317.0M | -$234.0M | -$166.0M | $73.0M | $318.0M | $290.0M | — |
| Income tax | $35.0M | $71.0M | $82.0M | $58.0M | $125.0M | $307.0M | — |
| Net income | -$360.0M | -$317.0M | -$260.0M | $6.0M | $182.0M | -$18.0M | — |
| EPS, basic | -1.02 | -0.90 | -0.74 | 0.02 | 0.52 | -0.05 | — |
| EPS, diluted | -1.02 | -0.90 | -0.74 | 0.02 | 0.52 | -0.05 | — |
| Shares, diluted (wtd. avg.) | 353.8M | 351.8M | 350.5M | 350.2M | 350.0M | 350.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $383.0M | $305.0M | $334.0M | $380.0M | $177.0M | $238.0M | $192.0M |
| Receivables | $1.22B | $1.03B | $839.0M | $724.0M | $721.0M | — | — |
| Inventory | $976.0M | $1.04B | $1.03B | $628.0M | $572.0M | — | — |
| Total current assets | $2.98B | $2.79B | $2.74B | $2.14B | $1.64B | — | — |
| Property, plant and equipment | $1.76B | $1.49B | $1.39B | $1.30B | $1.23B | — | — |
| Goodwill | $4.76B | $4.52B | $4.58B | $4.51B | $4.59B | $4.68B | $4.55B |
| Other intangibles | $3.28B | $3.49B | $3.59B | $2.06B | $2.26B | — | — |
| Total assets | $14.02B | $13.47B | $13.44B | $11.14B | $10.82B | — | — |
| Accounts payable | $388.0M | $389.0M | $522.0M | $370.0M | $239.0M | — | — |
| Short-term debt | $28.0M | $40.0M | $30.0M | $25.0M | $0 | — | — |
| Total current liabilities | $1.92B | $1.74B | $1.58B | $1.30B | $1.10B | — | — |
| Long-term debt | $5.02B | $4.74B | $4.53B | $2.41B | $0 | — | — |
| Total liabilities | $7.50B | $6.92B | $6.52B | $4.04B | $1.42B | — | — |
| Retained earnings | -$931.0M | -$571.0M | -$254.0M | $6.0M | $0 | — | — |
| Total equity | $6.45B | $6.47B | $6.92B | $7.10B | $9.40B | $9.99B | $10.03B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $283.0M | $232.0M | -$17.0M | $345.0M | $873.0M | $522.0M | — |
| Depreciation and amortisation | $163.0M | $148.0M | $142.0M | $135.0M | $123.0M | $119.0M | — |
| Stock-based compensation | $149.0M | $92.0M | $74.0M | $62.0M | $62.0M | $50.0M | — |
| Capital expenditure | $349.0M | $291.0M | $181.0M | $175.0M | $193.0M | $253.0M | — |
| Investing cash flow | -$455.0M | -$412.0M | -$2.11B | -$215.0M | -$214.0M | -$256.0M | — |
| Financing cash flow | $225.0M | $178.0M | $2.08B | $81.0M | -$712.0M | -$232.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-014234.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $3.41B | $3.77B | $3.77B | $4.15B | $4.79B | $5.10B |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$18.0M | $182.0M | $6.0M | -$260.0M | -$317.0M | -$360.0M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3851
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| COO | COOPER COMPANIES, INC. | $11.94B | 32.7x | 5.1% |
| WRBY | Warby Parker Inc. | $3.21B | 2,591.0x | 13.0% |
| EYE | National Vision Holdings, Inc. | $1.48B | 50.5x | 9.0% |
| STAA | STAAR SURGICAL CO | $1.13B | — | -23.7% |
| RXST | RxSight, Inc. | $208.8M | — | -3.9% |
| LUCY | Innovative Eyewear Inc | $7.5M | — | 62.6% |
| ALC | ALCON INC | — | — | 4.9% |